[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
June 1, 2005

NSAID Studies Abound in Cancer Research

JAMA. 2005;293(21):2579-2580. doi:10.1001/jama.293.21.2579

Some nonsteroidal anti-inflammatory drugs (NSAIDs) have come under fire recently because of their link to increased risk of myocardial infarction and stroke. But increasing evidence suggests the value of some of these drugs for certain cancer patients may outweigh such risks, according to findings presented at the annual meeting of the American Association for Cancer Research, held in Anaheim in April.


One new study highlighted at the conference revealed the effects of the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib on gene expression in the colon of individuals genetically at risk for hereditary nonpolyposis colon cancer. Previously reported epidemiological studies have shown that COX-2 inhibitors suppress colorectal carcinogenesis and reduce the risk of death from colorectal cancer, and these new results may point to the mechanisms by which this is accomplished.

First Page Preview View Large
First page PDF preview
First page PDF preview